FLC
ENZ

Fifth Lane Capital’s Enzo Biochem, Inc. ENZ Stock Holding History

Fifth Lane Capital’s Portfolio ENZ Stock Details ENZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-85,000
Closed -$156K – 252
2023
Q2 		$156K Buy
85,000
+30,139
+55% +$69.8K 0.05% 108
2023
Q1 		$133K Buy
+54,861
New +$81.6K 0.08% 76

Other funds holding ENZ

HFA
Harbert Fund Advisors Birmingham, Alabama $3.03M AUM 40.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCM
Potomac Capital Management New York $115M AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RC
RBF Capital San Francisco, California $2.05B AUM 29.64% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Fifth Lane Capital's ENZ Position: Q3 2023 in Review

Fifth Lane Capital sold out of Enzo Biochem, Inc. (ENZ) in Q3 2023, closing a stake of 85,000 shares — an estimated $156K sold.

Fifth Lane Capital first reported a position in ENZ in Q1 2023 and held it in 2 quarters. The position peaked at $156K in Q2 2023. 39 funds tracked by Wall St. Rank hold ENZ as of Q3 2023.

  • Fifth Lane Capital reported no remaining Enzo Biochem, Inc. position as of Q3 2023 after selling out during the quarter.
  • Fifth Lane Capital sold 85,000 Enzo Biochem, Inc. shares in Q3 2023, an estimated $156K.
  • Fifth Lane Capital first reported a position in Enzo Biochem, Inc. in Q1 2023 and held it in 2 quarters.
  • Fifth Lane Capital's Enzo Biochem, Inc. position peaked at $156K in Q2 2023.
  • 39 funds tracked by Wall St. Rank held Enzo Biochem, Inc. as of Q3 2023.

Based on Fifth Lane Capital's 13F filing for Q3 2023, filed 14 Nov 2023.